Yujin Hoshida, M.D., Ph.D.
Titles and Appointments
Director of Liver Tumor Translational Research
Professor
- Endowed Title
- H. Ray and Paula Calvert Chair in Gastroenterology Oncology in Honor of Udit Verma, M.D.
- School
- Medical School
- Department
- Internal Medicine
- Graduate Programs
- Cancer Biology
Yujin Hoshida, M.D., Ph.D., is a Professor in the Department of Internal Medicine at UT Southwestern Medical Center, and a member of the Division of Digestive and Liver Diseases. He serves as Director of the Liver Tumor Translational Research Program.
Originally from Japan, Dr. Hoshida received his medical degree from the University of Tsukuba and completed internal medicine residency training and a fellowship in clinical gastroenterology and hepatology, diagnostic pathology, diagnostic and interventional radiology, and biostatistics at the University of Tokyo and Toranomon Hospital. He then earned his doctoral degree in medical sciences from the University of Tokyo's Graduate School of Medicine. After postdoctoral training in cancer genomics and systems biology at the University of Tokyo's Research Center for Advanced Science and Technology and at the Broad Institute of MIT and Harvard University, he was recruited to join the faculty of the Tisch Cancer Institute of the Icahn School of Medicine at Mount Sinai and later came to UT Southwestern to direct the Liver Tumor Translational Research Program.
Dr. Hoshida has expertise in molecular classification, prognostic prediction, molecular targeted therapies, and chemoprevention in liver cirrhosis and cancer. He has been leading several international translational liver cirrhosis/cancer genomics projects, including Precision Liver Cancer Prevention Consortium, utilizing high-throughput omics technologies and integrative clinical and cross-species systems biology analysis over the past decade. The current focuses of his team include liver cancer risk-predictive molecular biomarkers specific to clinical contexts (e.g., geographic region, liver disease etiology, and patient race/ethnicity), individual risk-stratified personalized cancer screening based on cost-effectiveness, chemoprevention target discovery, radiogenomics, molecular subtype-guided liver cancer therapies, and informatics methodology and software by utilizing patient-derived tissues/cells, liquid biopsy of circulating biomolecules, single-cell omics, molecular digital spatial tissue profiling, clinical diagnostic platforms, nanomedicine technologies, and high-power computation.
Dr. Hoshida is an active member of several professional organizations, including the American Association for Cancer Research, the American Association for the Study of Liver Disease, the American Gastroenterological Association, and the American Society of Clinical Oncology.
Featured Publications